Partnering with Boehringer Ingelheim
Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
Search
AMR_Action_Fund
Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
Pipeline - March 2023.pdf
January 2023 Updated Pipeline Infographic
Pipeline 2023
2023 Pipeline Infographic.pdf
pipeline-june-2023
pipeline-october-2023
pipeline-february-2024
2024 February pipeline
collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Across Cancer Types
Across Cancer Types
Heidelberg Transforming Science Day 2025 - Save the Date
The Heidelberg Transforming Science Day profiles what makes our innovation different including our ground-breaking research and our diverse pipeline.
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Therapeutics
Therapeutics
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Transforming Science Day Europe
Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets
Breakthrough Designation granted in US and China
SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares
Mental Disorders
Mental Disorders
Cancer
Cancer
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced